Telo Genomics Corp., a molecular diagnostics company, develops and commercializes diagnostic and prognostic products to personalize treatment plans for patients with specific conditions in Canada and Internationally. The company's TeloView platform analyzes telomere structure and genomic instability to support disease prediction, risk assessment, and treatment selection. Its products include TeloView-SMM for smoldering multiple myeloma patients at risk of progression to multiple myeloma, TeloView NDMM for newly diagnosed multiple myeloma patients, TeloMRD-D for minimal residual disease detection, TeloViewNG-MRD for genomic instability profiling of residual disease cells, and TeloViewHL for Hodgkin's lymphoma. The company also has a collaboration agreement with the Mayo Clinic for product development activities. Telo Genomics Corp. is headquartered in Toronto, Canada.…
Telo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells
Telo Genomics (CVE: TELO) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector.
The shares were at 0.0400 CAD on 20 November 2026, down 42.9% over 52 weeks. Its 52-week range is 0.0250 CAD to 0.1050 CAD: the price is 61.9% below the high and 60.0% above the low.
Its market capitalisation is 4.02M CAD.
Telo Genomics reports an operating margin of 0.0%.
Its debt exceeds its cash by 1.11M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 November 2026.